 | By First Choice Neurology The FDA cleared Fujirebio's Lumipulse Plasma Ratio blood test for the early detection of amyloid plaques associated with Alzheimer's disease (AD). Lumipulse is the first in-vitro diagnostic (IVD) test used in the diagnosis of AD.
|
By NeuraWorx Medical Technologies, Inc. NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience.
|
 | By Memory Centers of America Memory Centers of America offers rapid evaluation and treatment of Alzheimer's disease.
|
By YouthBio Therapeutics YouthBio Therapeutics (YouthBio), a pioneering longevity biotechnology company developing partial reprogramming-based gene therapies, today announced significant research results from its collaboration with Dr.
|
 | By First Choice Neurology Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
|
 | By First Choice Neurology First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr.
|
